Calendula Officinalis L.: Study for Prospects of Creating Combined Dosage Forms with Naturally Similar Properties

Calendula officinalis L. is a part of almost 200 dosage forms. Despite the long tradition of use, the genus has not been properly studied. Pharmacological studies show that C. officinalis exhibits antibacterial, antiviral, anti-inflammatory, antitumor and antioxidant properties. A multidisciplinary and comprehensive study of calendula (Calendula officinalis L.) and a review of several medicinal plant raw materials with a similar content of biologically active substances were conducted for the prospects of creating combined dosage forms with naturally similar properties based on them. As well as a study of medicinal plant raw materials with a similar composition of biologically active substances. A review of the literature showed that quite a few drugs with different pharmacological effects have been created from the raw material of calendula officinalis, such as Gastrofit, calendula tincture, calendula ointment, Clotrex, Bronhofit, Ugrin®, Phytodent®, Rotokan, Tazalok™ and others. The task was set to create combined drugs, combined dosage forms with naturally similar properties using analogues of chemical-pharmaceutical origin (synthesis) of known pharmacological substances (active pharmaceutical ingredients), as well as medicinal plant raw materials using the example of raw materials of calendula flowers, hemp flowers, their introduction into industrial pharmaceutical production and medical practice, or individual manufacture according to a doctor's prescription in pharmacies while ensuring their quality, safety, effectiveness and economic availability.